Syndax Pharmaceuticals Gets U.K. Patent For Entinostat
Syndax Pharmaceuticals Inc. received a U.K. patent for entinostat. The histone deacetylase inhibitor is in multiple Phase II clinical studies including advanced breast cancer, metastatic lung cancer and other cancer types. The patent issuance extends entinostat’s exclusivity to 2029. Syndax is a Waltham, Mass.-based drug company that holds rights to entinostat from Bayer Schering Pharma. It is backed by Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures.
15 October 2010•3 mins read
